The PI3K/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis. 3-Phosphoinositidedependent protein kinase 1 (PDK1) is a Ser/Thr protein kinase, which catalyzes the phosphorylation of a conserved residue in the activation loop of a number of AGC kinases, including proto-oncogenes Akt, p70S6K, and RSK kinases. To find new small-molecule inhibitors of this important regulator kinase, the authors have developed PDK1-specific high-throughput enzymatic assays in time-resolved fluorescence resonance energy transfer (TR-FRET) and AlphaScreen ® formats, monitoring phosphorylation of a biotinylated peptide substrate derived from the activation loop of Akt. Development of homogeneous assays enabled screening of a focused kinase library of ~21,500 compounds in 1536-well TR-FRET format in duplicate. Upon validation of hits in an alternative 384-well AlphaScreen ® assay, several classes of structurally diverse PDK1 inhibitors, including tetracyclics, tricyclics, azaindoles, indazoles, and indenylpyrazoles, were identified, thus confirming the utility and sensitivity of the developed assays. Further testing in PC3 prostate cancer cells confirmed that representatives of the tetracyclic series showed intracellular modulation of the PDK1 activity, as evident from decreased phosphorylation levels of AKT, RSK, and S6-ribosomal protein. (Journal of Biomolecular 
INTRODUCTION
T he PI3K/PTeN/AKT-sIgNAlINg PAThwAy is deregulated in a majority of human solid tumors and plays a key role in cancer cell growth, survival, and tumor angiogenesis.
Several agents targeting different components of this pathway are in clinical development, including small-molecule inhibitors of PI3K, mTOR, and Akt. 1,2 3-Phosphoinositidedependent protein kinase 1 (PDK1) phosphorylates an important regulatory site in the activation loop (T-loop) of numerous AGC kinases, including Akt, p70, and p90 ribosomal S6-kinase (S6K and RSK), as well as protein kinase C (PKC). 3 The attractiveness of PDK1 as an anticancer target is based on its ability to regulate these kinases, with PDK1 null (PDK1 -/-) ES cells being devoid of Akt, p70S6K, and RSK activity. 4 Thus, inhibition of PDK1 might mitigate tumorigenesis by downregulating the signaling through the PI3K/PTEN pathway.
Feldman et al. 5 and Islam et al. 6 have described a series of potent indolinone-based PDK1 inhibitors (BX-795, BX-320, and BX-517 with 6-to 30-nM potency). They have demonstrated that these compounds block Akt signaling in cancer cells, cause cell cycle arrest and/or apoptosis, and inhibit transformationdependent growth. 5, 6 BX-320 also inhibited tumor growth of a LOX melanoma cell line in nude mice; however, caution has been raised about the specificity of these compounds because they also target kinases involved in cell cycle control (Cdk1, Cdk2, and Aurora A). 7, 8 However, a recent chemical genetic approach, which developed allele-specific PDK1 inhibitors using the BX-795 scaffold and PDK1 -/-ES cells, reinforces the concept of pharmacological inhibitors of PDK1 as candidate anticancer agents. 7 In light of the compelling evidence for the role of PI3K/ PTEN/Akt signaling in cancer progression, we sought to discover novel small-molecule inhibitors that block this pathway for evaluation as anticancer drugs. An indirect monitoring of PDK1 activity in an Akt-coupled kinase activity screening assay has been reported before, 9, 10 where activation of Akt kinase by PDK1 was measured by quantitating the phosphorylation of GSK-3a peptide, used as a downstream Akt-specific substrate. To date, no high-throughput approaches directly targeting PDK1 kinase have been described in the literature. Our strategy was to develop high-throughput screening (HTS)-amenable assays for direct monitoring of the PDK1-mediated phosphorylation of the Akt T-loop peptide.
In this article, we report the development of novel PDK1specific enzymatic assays in 2 homogeneous detection formats: Merck Research Laboratories, Boston, Massachusetts. time-resolved fluorescence resonance energy transfer (TR-FRET) and amplified luminescent proximity homogeneous assay (AlphaScreen ® ). Using a TR-FRET assay, we screened a focused library of ~21,500 compounds in a 1536-well format, followed by reconfirmation of hits in a chemiluminescent AlphaScreen ® to eliminate format-specific artifacts. This screening approach proved to be effective by identifying several classes of hits. The initial characterization of low-nanomolar potency tetracyclic analogs presented here, which are also capable of blocking the phosphorylation of PDK1 substrates in cells, provides a proof of utility for the developed high-throughput assays for identification of novel inhibitors targeting PDK1.
MATERIALS AND METHODS
AlphaScreen ® general IgG (protein A) detection kit, white opaque 384-well Optiplates, and LANCE Eu-W1024-labeled antirabbit IgG antibody were purchased from PerkinElmer, Life and Analytical Sciences (Waltham, MA). The 384-well black plates were from Greiner Bio-One GmbH (Frickenhausen, Germany). Anti-phospho-Akt (T308) monoclonal antibody was obtained from Cell Signaling Technologies (Danvers, MA). Streptavidin-linked DyLight fluorophore was purchased from Pierce (Woburn, MA). Streptavidin-APC was obtained from Prozyme (San Leandro, CA). Activated recombinant full-length human PDK1, with a middle T tag at its N-terminus (MEYMPME) and a MW of 64 kDa, was expressed and purified to >90% purity at Kemp Biotechnologies (Frederick, MD). The 5× kinase buffer was obtained from Invitrogen (Carlsbad, CA). Substrate peptide Biotin-GGDGATMKTFCGGTPSDGDPDGGEFTEF-COOH, containing the activation loop segment of AKT(T308), was synthesized at the W. M. Keck Biotechnology Resource Center of Yale University (New Haven, CT). For Western blotting, the following antibodies were used: b-actin, phospho-AKT(308), and phospho-S6Ribosomal Protein (S235/236) from Cell Signaling Technologies (Danvers, MA) and phospho-RSK1(S211/227) from Invitrogen.
Optimization of enzyme concentration and K m determinations
For optimization of enzyme levels, 20-mL TR-FRET reactions in 384-well plates, containing 300 nM biotinylated Akt peptide, 5 mM adenosine triphosphate (ATP), 5 mM MgCl 2 , 2 mM dithiothreitol (DTT), and 5 % (v/v) DMSO in 1× kinase assay buffer (10 mM HEPES [pH 7.5], 0.002% Brij-35, 0.2 mM EGTA), were carried out under various PDK1 concentrations in the range of 0.1 to 2.5 nM.
The apparent K m values for ATP and Akt-peptide substrates were obtained using a pseudo-first-order approach, where the final concentrations of substrates were varied from 5 to 200 mM for ATP, with a fixed concentration of 0.1 mM for the Akt-peptide substrate, or from 0.05 to 1 mM for Akt-peptide, and the concentration of ATP was fixed at 250 mM, respectively.
To generate initial rates, reactions were started by the addition of one of the substrates and stopped at various incubation times with the Developing Buffer, containing 10 mM EDTA, 1 nM anti-phospho-Akt T308 primary monoclonal antibody, 5 nM LANCE Eu-W1024-labeled antirabbit IgG secondary antibody, and 50 nM SA-DyLight. After a 2-h incubation at room temperature to allow for an efficient coupling, formation of the phospho-Akt product was detected on the Envision plate reader from PerkinElmer. Fluorescent signal ratios at 615 nM/665 nM were calculated to assess TR-FRET.
TR-FRET PDK1 kinase screening assays
Eleven-point dose-response testing in the 384-well format was done in duplicate with all liquid dispense steps performed using Biomek FX Workstation (Beckman Coulter, Fullerton, CA). Then, 1 mL of test compounds, serially diluted in 100% DMSO, was predispensed into the dry wells. The 20-mL reaction contained 0.5 nM activated PDK1, 300 nM biotinylated AKT peptide, 5 mM ATP, 5 mM MgCl 2 , 2 mM DTT, 5% (v/v) DMSO, and 0 to 30 mM test compound in 1× Kinase Assay Buffer. The reactions were started with the addition of ATP and stopped at 30 min with the addition of 20 mL of the Developing Buffer. TR-FRET was detected as described above, and percent inhibition was calculated for each concentration. To determine IC 50 values, dose-response curves were generated by nonlinear regression fit using the 4-parameter binding model.
For single-point screening in the 1536-well format, the optimized reaction conditions were 2.5 nM activated PDK1, 600 nM biotinylated AKT peptide, 10 mM ATP, 5 mM MgCl 2 , 2 mM DTT, 5% (v/v) DMSO, and 10 mM test compound in 1× Kinase Assay Buffer with a total reaction volume of 4 mL. Reactions were started by the addition of ATP and stopped after 30 min with 4 mL of the Developing Buffer, supplemented with 10 mM EDTA, 5 nM anti-phospho-Akt T308 primary monoclonal antibody, 5 nM LANCE Eu-W1024-labeled antirabbit IgG secondary antibody, and 100 nM streptavidin-APC. After a 1-h incubation to allow for an efficient antibodies coupling, TR-FRET was monitored on the ViewLux plate reader from PerkinElmer.
AlphaScreen ® PDK1 kinase screening assay
A secondary confirmation assay in an alternate format, AlphaScreen ® , was developed to aid with validation of the hits identified in a primary TR-FRET screen. The reconfirmation screen was performed in a total reaction volume of 10 mL per well at 1 nM activated PDK1, 25 nM biotinylated Akt peptide, 10 mM ATP, 5 mM MgCl 2 , 100 mM NaCl, 2 mM DTT, and 10% DMSO in 1× Kinase Assay Buffer. After a 40-min incubation, reactions were stopped by the addition of 5 mL EDTA to a final concentration of 20 mM. Upon an additional 30-min incubation, an addition of 5 mL of the Acceptor beads, diluted 1:15 (v/v) with the AlphaScreen ® Developing Buffer to achieve a concentration of 0.3 mg/mL, was followed by the addition of 5 mL of 1:15 (v/v) diluted Donor beads, resulting in a 0.3-mg/mL final concentration. After shaking of the plates in the dark for 120 min, fluorescence was measured at a wavelength 520 to 620 nM using Envision. Compounds were tested in duplicate.
Phospho-signaling by Western blots
PC3 cells grown in 6-well plates to 80% confluency were treated with compounds or DMSO control, then washed with icecold phosphate-buffered saline (PBS) and resuspended in lysis buffer (20 mM Tris [pH 7.5], 150 mM NaCl, 15% [v/v] glycerol, 1% [v/v] Nonidet P-40 (NP-40), 2 mM phenylmethylsulfonyl fluoride, 1 mM sodium vanadate, 25 mM b-glycerol phosphate, 50 mM NaF, 10 mM sodium pyrophosphate). Cell lysates were clarified by centrifugation, solubilized in 2× sodium dodecyl sulfate (SDS) loading buffer, separated by 4% to 12% Nupage Bis-Tris gel, and transferred to a nitrocellulose membrane for Western blotting. Membranes were blocked in 5% nonfat milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 and probed with primary and secondary horseradish peroxidase (HRP)-conjugated antibodies. Immunoreactive proteins were visualized using enhanced chemiluminescence on film.
RESULTS AND DISCUSSION

Development and validation of PDK1 screening assays
A drawback of the coupled PDK1-Akt cascade screening approach 9,10 for identification of PDK1 inhibitors is a suboptimal sensitivity toward PDK1 inhibitors due to a very significant difference in affinity for ATP between these 2 kinases. 10, 11 A direct PDK1 screening assay based on phosphorylation of a biotinylated Akt-peptide not only would allow an optimization for the detection of its specific inhibitors but would also monitor only the activity of an intended target, thus eliminating a need for deconvolution of the hits that inhibit the Akt kinase.
To optimize screening substrate concentrations in the TR-FRET assay, we determined the apparent K m values as 5.7 mM for ATP and 0.3 mM for the Akt-peptide, as shown in Figure 1A and 1B, respectively. A pseudo-first-order reaction approach was used to overcome the limitations of the achievable levels of streptavidinlinked DyLight Fluor to avoid signal saturation due to high concentrations of the biotinylated peptide. The screening concentrations for the potency testing in a 384-well format were chosen at 5 mM of ATP and 0.3 mM for the peptide substrate.
Further optimization of the assay statistics was performed by comparing Z′ factor values 12 derived at different reaction times under various concentrations of the PDK1 enzyme to ensure linearity and a level of the substrate transformation not exceeding 30%. As shown in Table 1 , with the enzyme concentration of 1 nM and a 30-min incubation time, a Z′ factor value of ~0.6 was achieved in the 384-well format.
Validation of the 384-well assay with the previously described BX-795 inhibitor of PDK1 generated an IC 50 of 7.8 ± 1.4 nM, in good agreement with the literature value of 11 nM, 5 thus confirming sensitivity of the resulting structure-activity relationship (SAR) assay toward inhibitors.
To decrease reagents consumption and the time necessary for interrogation of compound libraries by focused screening, we further miniaturized the assay into the 1536-well format. To achieve acceptable statistics for the single-point screening in a 1536-well format, we improved the signal-to-background ratio by increasing the substrate concentrations to 10 mM for ATP and 0.6 mM for Akt-peptide while ensuring the linearity of the reaction time course, which resulted in a Z′ factor of 0.6.
To eliminate format-related artifacts, a secondary AlphaScreen ® assay was developed to reconfirm hits in a format different from the primary TR-FRET. Like TR-FRET, AlphaScreen ® is a proximity-based approach, and thus the same biotinylated peptide substrate and antibodies can be used for the capture of the reaction product during the detection step of the assay, saving time needed for the development of custom reagents.
Because of a limiting biotin-binding capacity of the Acceptor beads, the critical issue for the development of the AlphaScreen ® assay was optimization of the biotinylated Akt substrate peptide concentration versus the concentration of the streptavidin-coated beads. To optimize concentration of the biotin binding sites for an efficient binding of the phosphorylated peptide product, reactions were performed at various concentrations of the biotintagged substrate peptide (20-150 nM) and detected using various concentrations of the beads (0.01-0.66 mg/mL). As shown in Figure 2 , at a concentration 0.2 mg/mL of the Acceptor beads, an optimal signal is reached at about ~50 nM of the biotinylated substrate. A further increase of the biotinylated substrate levels in the reaction leads to the decrease in signal because of the competition between phosphorylated (product) and nonphosphorylated (substrate) biotinylated peptides for the streptavidin binding sites on the beads, causing a well-known "hooking" effect. To ensure that there is a sufficient supply of biotin binding sites for an optimal detection of the reaction product, we chose a screening substrate peptide concentration of 25 nM at the Acceptor beads concentration of 0.3 mg/mL. Under the optimized conditions, a Z′ factor of 0.6 was achieved.
Although AlphaScreen ® proved to be superior to TR-FRET as to the signal window, the application of this technology to the primary ultra-HTS is limited by a lower biotin-capturing capacity due to the donor beads concentration achievable in the solution. Under the recommended conditions, the biotin capacity can be raised only up to ~100 nM, whereas the optimal screening peptide substrate concentrations at the ~1× K m level are usually in a micromolar range for many kinase systems. AlphaScreen ® detection reagents are more expensive than TR-FRET counterparts, and during the conveyor type, ultra-HTS operations would also require specialized mixing equipment to accurately aliquot the beads suspension. These factors limit the utility of the AlphaScreen ® technology for the primary ultra-HTS but make it a good choice as an alternative approach for validation of the hits and/or screening of limited libraries when substrate concentration is not an issue.
Focused screen results
A kinase-focused collection of ~21,500 compounds was comprised from smaller targeted libraries, such as kinase-biased, structure-guided, and low molecular weight fragment subsets, with a random drug-like library included as an internal control. The compound libraries and computational approaches used to compile them are described in more detail by Sun et al. 13 The focused collection of ~21,500 compounds was screened at 10 mM of test compounds in duplicate using the TR-FRET readout in the 1536-well format. Screening in an ultra-highthroughput format afforded duplicate measurements instead of a common single point, thus generating data of much higher quality and eliminating a necessity for reconfirmation in a primary assay. Consistent with expectation, the hit rate of 6.2% for the kinase-targeted collection was an order of magnitude higher than that of the random compound library (0.3%). The Z′ factor was calculated as described by Zhang et al. 12 The chemiluminescent detection in AlphaScreen ® allows measurements in a shorter wavelength range than for TR-FRET, providing the means for discerning false-positive hits that spectrally interfere during the detection step from the true modulators of the enzyme activity. To sort out possible spectral interferers, we tested primary hits in an AlphaScreen ® secondary assay at a 10-mM test compound concentration in duplicate, resulting in a reconfirmation rate of ~69%.
Computational analysis of the hits revealed 263 distinct clusters. About 14% of the hits were represented by singletons, and about 20% grouped into smaller clusters with ≤5 members, thus confirming the utility of focused screening for identification of structurally diverse leads. The majority of the hits belonged to several large classes of known kinase scaffolds, such as tetracyclics, tricyclics, azaindoles, indazoles, and indenylpyrazoles. A more detailed description of the cluster analyses of the focused library and the screen results, as well as corresponding computational approaches employed, has been reported in a separate publication. 13
Preliminary SAR
To derive preliminary SAR, we generated IC 50 values for the top 300 compounds by monitoring PDK1 activity in the TR-FRET assay. A class of tetracyclic small-molecule PDK1 inhibitors, identified in this screen and characterized by Merck & Co. Inc., 14 using the subject TR-FRET PDK1 assay, was chosen for further chemical exploration ( Table 2) . Some of the structures reported here were also reviewed in a recent article by Peifer and Alessi. 15 In this initial SAR study, it was observed that there were both steric and electronic contributions of the R 1 substituent toward potency. Sterically demanding alkyl and aryl substituents displayed the most favorable potency (e.g., compound 1, R 1 = t-Bu IC 50 = 0.9 nM), whereas electron-withdrawing R 1 groups were associated with lower potency (e.g., compounds 6 and 8, R 1 = CF 3 IC 50 = 35 nM, R 1 = sulfone IC 50 = 465 nM, respectively). Importantly, an alkoxymorpholino moiety at the R 2 position was tolerated and appears to provide a potential handle to modulate physicochemical properties. Although compound 1 has been previously described as a potent JAK3 inhibitor, 16 we were encouraged about its potential as a lead for PDK1 because we observed 5-fold more potent inhibition of PDK1 relative to JAK3 under the concentrations of substrates at 1× K m for both kinases.
Tetracyclic PDK1 inhibitors block the PDK1 pathway in cells
On the basis of the favorable enzymatic potencies of these compounds, we next characterized the ability of tetracyclic PDK1 inhibitors to block the PI3K/Akt pathway in PC3 prostate cancer cells. PC3 cells are PTEN-null and display constitutive activation of the PI3K pathway, as measured by phosphorylation of Akt(T308) and S6-ribosomal protein(S235/S236). PC3 cells also express significant levels of p90RSK kinase-another direct substrate of PDK1, with residue Thr221 being the homologous site to Thr308 in Akt. 4 Because phosphospecific antibodies are available for both Akt(T308) and RSK(T221), the inhibition of PDK1 activity in cells can be monitored using standard Western blotting techniques. When PC3 cells were treated with and without compounds for 2 h followed by Western blotting on cell extracts, we found that compounds 1, 4, 5, and 7 were as potent or more potent in inhibiting the phosphorylation of AKT and RSK compared to BX-795 ( Fig. 3) . Consistent with this result, compounds 1, 4, and 5 are all single-digit nanomolar inhibitors of the PDK1 enzyme ( Table 2) . For comparison, the least potent inhibitor (compound 8) was inactive in PC3 cells. Unexpectedly, however, compounds 2 and 3, which are close analogs of compound 1 (IC 50 values <5 nM), were not potent in cells when compared to DMSO treatment. Interestingly, compound 3 showed a significant inhibition of phospho-Akt with minimal inhibition of phospho-RSK. This disconnect suggests that compound 3 may have potent off-target activities against additional kinases upstream of Akt, including receptor tyrosine kinases (RTKs). Because inhibition of RTKs, as well as smallmolecule inhibition of PI3K, does not inhibit T-loop phosphorylation of RSK but preferentially inhibits PI3K-dependent substrates such as Akt, we propose the dual monitoring of Akt(T308) and RSK(S221) as a cell biochemical screening paradigm for further optimization of selective cell potency.
A meaningful SAR observed for the identified lead series, combined with the first evidence of an intracellular modulation of the PDK1 function, provided an ultimate proof of the practical usefulness of the screening assays reported herein.
CONCLUSIONS
In modern molecular drug discovery, availability of sensitive target-specific screening assays is a crucial prerequisite to finding new scaffolds and optimizing leads to clinically useful drugs. Development of 2 novel homogeneous high-throughput assays for direct monitoring of PDK1 kinase activity not only enables the search for new inhibitors but also facilitates SAR studies for this key regulator of many oncogenic responses, as was successfully demonstrated in this article. With known limitations of ultra-HTS random screening campaigns as relatively expensive and time-consuming, an effective complementary and/or alternative approach might be a focused screening of smaller targeted collections to generate tool compounds and accelerate initiation of SAR studies. With recent developments in computational approaches, target-biased libraries can be complemented with structure-guided and virtual screening approaches to increase the chance of identifying new inhibitor scaffolds, as was shown by this work. With several additional factors to consider, such as the cost of acquisition and availability of compounds for purchase, as well as the expense of storage and compound management, it might make a better choice to use a focused screening approach to jumpstart a drug discovery program. In this study, we demonstrated that with proper design and availability of sensitive screening assays, a focused approach enables identification of structurally diverse inhibitors by screening a limited but targeted compound collection.
